Cargando…

Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status

Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Naoya, Ishii, Mariko, Kawauchi, Yoko, Takagi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810488/
https://www.ncbi.nlm.nih.gov/pubmed/24224170
http://dx.doi.org/10.1155/2013/562924
_version_ 1782288795224244224
author Kojima, Naoya
Ishii, Mariko
Kawauchi, Yoko
Takagi, Hideaki
author_facet Kojima, Naoya
Ishii, Mariko
Kawauchi, Yoko
Takagi, Hideaki
author_sort Kojima, Naoya
collection PubMed
description Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant implications for vaccine design. In this paper, we summarize the potential for liposomes coated with the neoglycolipids containing oligomannose residues (OMLs) as a novel adjuvant for induction of Th1 immune responses and CTLs specific for the encased antigen. OMLs preferentially take up peripheral phagocytic cells. In response to OML uptake, the cells secrete IL-12 selectively, enhance the expression of costimulatory molecules, and migrate into lymphoid tissues from peripheral tissues. OMLs also have the ability to deliver encapsulated protein antigens to the MHC class I and class II pathways to generate antigen-specific CTLs and Th1 cells, respectively, and lipid antigen to CD1d to activate NKT cells. Since administration of OML-based vaccines can eliminate an established tumor, inhibit elevation of the serum IgE level, and prevent progression of protozoan infections in several murine, human, and bovine models, OML-based vaccines have revealed their potential for clinical use in vaccination for a variety of diseases in which CTLs and/or Th1 cells act as effector cells.
format Online
Article
Text
id pubmed-3810488
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38104882013-11-10 Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status Kojima, Naoya Ishii, Mariko Kawauchi, Yoko Takagi, Hideaki Biomed Res Int Review Article Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant implications for vaccine design. In this paper, we summarize the potential for liposomes coated with the neoglycolipids containing oligomannose residues (OMLs) as a novel adjuvant for induction of Th1 immune responses and CTLs specific for the encased antigen. OMLs preferentially take up peripheral phagocytic cells. In response to OML uptake, the cells secrete IL-12 selectively, enhance the expression of costimulatory molecules, and migrate into lymphoid tissues from peripheral tissues. OMLs also have the ability to deliver encapsulated protein antigens to the MHC class I and class II pathways to generate antigen-specific CTLs and Th1 cells, respectively, and lipid antigen to CD1d to activate NKT cells. Since administration of OML-based vaccines can eliminate an established tumor, inhibit elevation of the serum IgE level, and prevent progression of protozoan infections in several murine, human, and bovine models, OML-based vaccines have revealed their potential for clinical use in vaccination for a variety of diseases in which CTLs and/or Th1 cells act as effector cells. Hindawi Publishing Corporation 2013 2013-10-10 /pmc/articles/PMC3810488/ /pubmed/24224170 http://dx.doi.org/10.1155/2013/562924 Text en Copyright © 2013 Naoya Kojima et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kojima, Naoya
Ishii, Mariko
Kawauchi, Yoko
Takagi, Hideaki
Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title_full Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title_fullStr Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title_full_unstemmed Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title_short Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
title_sort oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810488/
https://www.ncbi.nlm.nih.gov/pubmed/24224170
http://dx.doi.org/10.1155/2013/562924
work_keys_str_mv AT kojimanaoya oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus
AT ishiimariko oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus
AT kawauchiyoko oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus
AT takagihideaki oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus